EP1594959A4 - Neues therapeutisches verfahren und zusammensetzungen zur topischen verabreichung - Google Patents

Neues therapeutisches verfahren und zusammensetzungen zur topischen verabreichung

Info

Publication number
EP1594959A4
EP1594959A4 EP04711167A EP04711167A EP1594959A4 EP 1594959 A4 EP1594959 A4 EP 1594959A4 EP 04711167 A EP04711167 A EP 04711167A EP 04711167 A EP04711167 A EP 04711167A EP 1594959 A4 EP1594959 A4 EP 1594959A4
Authority
EP
European Patent Office
Prior art keywords
compositions
topical administration
therapeutic method
novel therapeutic
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04711167A
Other languages
English (en)
French (fr)
Other versions
EP1594959A2 (de
Inventor
Adrian Francis Davis
Lionel Trottet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1594959A2 publication Critical patent/EP1594959A2/de
Publication of EP1594959A4 publication Critical patent/EP1594959A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04711167A 2003-02-17 2004-02-13 Neues therapeutisches verfahren und zusammensetzungen zur topischen verabreichung Withdrawn EP1594959A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
GB0303609 2003-02-17
PCT/US2004/004329 WO2004073622A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Publications (2)

Publication Number Publication Date
EP1594959A2 EP1594959A2 (de) 2005-11-16
EP1594959A4 true EP1594959A4 (de) 2006-05-03

Family

ID=9953158

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04711167A Withdrawn EP1594959A4 (de) 2003-02-17 2004-02-13 Neues therapeutisches verfahren und zusammensetzungen zur topischen verabreichung

Country Status (4)

Country Link
EP (1) EP1594959A4 (de)
JP (1) JP2006517973A (de)
GB (1) GB0303609D0 (de)
WO (1) WO2004073622A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2396081T (pt) 2009-02-16 2017-07-11 Nogra Pharma Ltd Compostos alquilamido e suas utilizações
WO2011084824A1 (en) * 2009-12-21 2011-07-14 Sarah Bacus Compositions and methods for increasing cellular fat and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
BR112014026160A2 (pt) 2012-04-18 2017-07-18 Nogra Pharma Ltd métodos para tratar intolerância à lactose
EP2968298B1 (de) 2013-03-14 2018-01-31 Deuterx, LLC Mit deuterium angereicherte 2,4-thiazolidindione und behandlungsverfahren
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
EP3500260A1 (de) 2017-02-22 2019-06-26 Sugarman, Jeffrey, L. Glitazone zur topischen anwendung
EA202192207A1 (ru) 2019-02-08 2021-10-27 Ногра Фарма Лимитед Способ получения 3-(4'-аминофенил)-2-метоксипропионовой кислоты и ее аналогов и промежуточных соединений
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2002076177A2 (en) * 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2002076177A2 (en) * 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUENZLI S ET AL: "EFFECT OF TOPICAL PPARBETA/DELTA AND PPARGAMMA AGONISTS ON PLAQUE PSORIASIS A PILOT STUDY", DERMATOLOGY, XX, XX, vol. 206, no. 3, 2003, pages 252 - 256, XP009061119, ISSN: 1018-8665 *

Also Published As

Publication number Publication date
GB0303609D0 (en) 2003-03-19
JP2006517973A (ja) 2006-08-03
WO2004073622A3 (en) 2005-01-20
WO2004073622A2 (en) 2004-09-02
EP1594959A2 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
TWI345979B (en) Topical pharmaceutical compositions for the treatment of dermatitis
ZA200409332B (en) Novel methods and compositions for alleviating pain
EP1513825A4 (de) Antituberkulöses arzneimittel: zusammensetzungen und verfahren
AU2002951833A0 (en) Compositions and therapeutic methods invloving platinum complexes
EP1603543A4 (de) Therapeutische zusammensetzungen
EP1594959A4 (de) Neues therapeutisches verfahren und zusammensetzungen zur topischen verabreichung
EP1648364A4 (de) Pharmazeutische zusammensetzungen für die topische applikation
EP1648474A4 (de) Verfahren und pharmazeutische zusammensetzungen zur wundheilung
ZA200600025B (en) Methods and compositions for interferon therapy
EP1608385A4 (de) Therapeutische zusammensetzungen
IL173148A0 (en) Methods and pharmaceutical compositions for healing wounds
HK1093896A1 (en) Medicinal composition
GB2392618B (en) Compositions for therapeutic use
GB0229258D0 (en) Medicinal compositions
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
GB0222945D0 (en) Therapeutic compositions
AU2003282722A8 (en) Therapeutic compositions
EP1600445A4 (de) Medizinische zusammensetzung
HK1081451A1 (en) Medicinal composition
EP1594496A4 (de) Neues therapeutisches verfahren und zusammensetzung für die topische verabreichung
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0327050D0 (en) Therapeutic methods compositions and uses
ZA200603126B (en) Pharmaceutical compositions for therapeutic use
HK1062274A1 (en) Medicinal composition
AU2003235931A1 (en) Vintoperol-containing medicinal composition for transdermal administration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050804

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20060321

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/425 20060101ALI20060315BHEP

Ipc: C12N 9/00 20060101AFI20050208BHEP

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20050804

Extension state: LT

Payment date: 20050804

17Q First examination report despatched

Effective date: 20061031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090522